BTN3A1 and cancer: This study underscores the importance of BTN3A1 in blunting protective antitumor T cell activity in the setting of cancer, and lays bare the proposition that targeting this immunosuppressive pathway may be more effective in unleashing protective immunity than the blockade of PD-1/PD-L1 in certain malignancies.